How Does Livial Work in the Body
Chemical Composition, Mechanism of Action & Metabolic Effects Explained
Key Takeaways: How Livial Works
- Active Ingredient: Tibolone – a synthetic steroid with oestrogenic, progestogenic, and androgenic properties.
- Tissue‑Specific Action: Metabolised in the body to produce hormone‑like effects in brain, bone, and vagina without stimulating the womb lining.
- Onset & Duration: Relief of menopausal symptoms (hot flushes) within weeks; continuous daily dosing maintains steady levels.
- Metabolism: Extensive first‑pass hepatic metabolism via CYP3A4 into three active metabolites.
- Unique HRT Option: Unlike standard HRT, Livial does not cause monthly withdrawal bleeding.
Livial is a unique form of hormone replacement therapy (HRT) that uses tibolone – a substance your body converts into three different active metabolites. These metabolites act selectively on oestrogen, progesterone, and androgen receptors, providing relief from menopausal symptoms while avoiding endometrial stimulation.
Important Medical Advice
Do not take Livial if you have or have had breast cancer, unexplained vaginal bleeding, liver disease, blood clots, or are pregnant. Stop Livial and seek immediate medical help if you develop jaundice, sudden migraine‑like headache, signs of a blood clot (painful leg swelling, sudden chest pain), or a significant rise in blood pressure.
Chemical Composition & Molecular Structure
Livial contains the active substance tibolone, chemically described as (7α,17α)-17‑hydroxy‑7‑methyl‑19‑nor‑17‑pregn‑5(10)-en‑20‑yn‑3‑one. It is a synthetic steroid with a molecular weight of 312.45 g/mol. Each Livial 2.5 mg tablet delivers 2.5 mg of tibolone together with excipients: potato starch, lactose monohydrate, ascorbyl palmitate, and magnesium stearate.
Structural Insights
19‑nortestosterone derivative with a 7α‑methyl and 17α‑ethynyl group
This unique structure allows tibolone to act as a prodrug. After oral administration, it undergoes rapid metabolic conversion into three active metabolites that exert tissue‑specific hormonal effects.
- Lipophilicity: High, enabling good oral absorption and tissue distribution.
- Protein binding: Approximately 96% bound to plasma proteins (albumin and SHBG).
- Bioavailability: Variable due to extensive first‑pass metabolism; systemic exposure depends on individual hepatic enzyme activity.
🗒️ Pharmaceutical note: The tablet is designed for once‑daily administration, with consistent dosing ensuring steady metabolite concentrations. The lactose content may be relevant for patients with rare hereditary galactose intolerance.
Mechanism of Action: Tissue‑Specific Tibolone Pathway
Livial works through a sophisticated prodrug mechanism. After ingestion, tibolone is rapidly converted in the liver and gut into three principal active metabolites: 3α‑hydroxy‑tibolone, 3β‑hydroxy‑tibolone, and the Δ4‑isomer. These metabolites act as tissue‑specific hormonal agents:
- 3α/3β‑hydroxy metabolites: Bind to oestrogen receptors (ERα and ERβ), producing oestrogen‑like effects in the brain (reducing hot flushes), vagina (improving dryness), and bone (preventing resorption). They do not significantly activate the endometrium because they are rapidly converted to the Δ4‑isomer in the endometrium.
- Δ4‑isomer: Possesses progestogenic and androgenic properties. It binds to progesterone receptors (PR) and androgen receptors (AR), providing protective effects on the endometrium and contributing to mood stability and libido.
This tissue‑specific activity is often described as a "selective oestrogen enzyme modulator" (SEEM) effect. Unlike conventional HRT, Livial does not stimulate the endometrium, eliminating the need for monthly withdrawal bleeding. It also reduces sex‑hormone‑binding globulin (SHBG), increasing free testosterone levels, which can improve sexual desire and wellbeing.
| Target Tissue | Primary Metabolite | Clinical Effect |
|---|---|---|
| Brain (hypothalamus) | 3α/3β‑OH | Reduction of hot flushes, night sweats |
| Bone (osteoblasts) | 3α/3β‑OH | Decreased bone resorption, increased bone density |
| Vagina | 3α/3β‑OH | Improved epithelial thickness, reduced dryness |
| Endometrium | Δ4‑isomer | No proliferation, minimal bleeding |
| Breast | Mixed | Increased breast cancer risk (see section 2) |
Absorption & Distribution (Pharmacokinetics)
Absorption: Tibolone is rapidly absorbed from the gastrointestinal tract after oral administration. Peak plasma concentrations of tibolone are reached within 1–2 hours, but the drug is quickly converted to its active metabolites, which appear in the circulation within 30 minutes.
Distribution: Due to high lipophilicity, tibolone and its metabolites distribute widely into tissues. The volume of distribution is approximately 1000 L. Protein binding exceeds 96%, mainly to albumin, with minimal binding to SHBG.
Steady state: With daily dosing, steady‑state concentrations of the metabolites are achieved within 5–7 days. The long half‑life of the metabolites (24–48 hours) supports once‑daily dosing.
Onset of Action
Symptom relief (hot flushes) often begins within 2–4 weeks of starting treatment, with full benefit seen by 3 months. Bone protection requires longer‑term use.
Duration of Effect
The tissue‑specific effects persist throughout the dosing interval; consistent daily intake maintains continuous hormonal activity without cyclic fluctuations.
Metabolic Effects & Elimination
Metabolism: Tibolone undergoes extensive first‑pass metabolism in the liver, primarily via the CYP3A4 enzyme. It is converted into the three active metabolites mentioned above. Further conjugation (sulfation, glucuronidation) produces inactive water‑soluble compounds.
Elimination: The metabolites and conjugates are excreted in urine (approximately 50%) and faeces (approximately 50%). The terminal half‑life of the active metabolites ranges from 24 to 48 hours, making once‑daily dosing appropriate.
Metabolic Effects on Lipids: Livial produces a dose‑dependent decrease in HDL cholesterol (by 16.7–21.8% with 1.25–2.5 mg doses). Total cholesterol, triglycerides, and lipoprotein(a) also decrease, while LDL cholesterol remains unchanged. The clinical significance of these changes is still under study, but they may contribute to cardiovascular risk profiles.
⚠️ Important: Patients with severe hepatic impairment may have reduced clearance of tibolone. Women with pre‑existing hypertriglyceridaemia should be closely monitored, as rare cases of pancreatitis have been reported with oestrogen therapy.
Clinical Efficacy in Menopause Management
Livial is indicated for the treatment of oestrogen deficiency symptoms in postmenopausal women (at least 12 months since last natural period). It effectively reduces the frequency and severity of moderate‑to‑severe hot flushes by 80–90% within 3–4 months. It also improves vaginal dryness, dyspareunia (painful intercourse), and urogenital atrophy.
Bone protection: Clinical studies demonstrate that Livial prevents postmenopausal bone loss in the spine and hip. It maintains or increases bone mineral density (BMD) when taken for at least 2–5 years, reducing the risk of osteoporotic fractures.
Mood and sexual wellbeing: Because Livial does not lower SHBG as much as oral oestrogens, free testosterone levels remain higher, often leading to improved libido, mood, and energy levels compared to conventional HRT.
Endometrial safety: Unlike combined HRT, Livial does not cause endometrial proliferation, and rates of endometrial hyperplasia and cancer are not increased with long‑term use (up to 10 years in clinical trials).
Livial FAQs
How long does it take for Livial to start working?
Hot flushes and night sweats often improve within 2–4 weeks, with maximum benefit by 3 months. Vaginal dryness may take 6–8 weeks, while bone protection requires continuous use for 2 years or more.
Does Livial cause weight gain?
Some women report mild weight gain, but clinical trials show no significant difference compared to placebo. Fluid retention can occur but is usually temporary.
Can I take Livial if I still have my womb?
Yes. Livial is suitable for women with a womb because its progestogenic activity protects the endometrium, unlike oestrogen‑only HRT which requires additional progestogen.
What is the risk of breast cancer with Livial?
Studies show that tibolone increases the risk of breast cancer, similar to combined HRT. The risk increases with duration of use and returns to baseline after stopping. Discuss personal risk factors with your doctor.
How do I switch from another HRT to Livial?
If you are on a cyclic HRT, start Livial after your next withdrawal bleed. If on continuous combined HRT, you can switch any day. Always follow your doctor’s instructions for a smooth transition.
Need Livial with Professional Guidance?
Understanding how Livial works helps you make an informed choice about menopause management. Our UK‑registered doctors can assess your suitability and prescribe Livial after an online consultation.
Secure Prescription & Next-Day Delivery
MHRA‑compliant | GPhC‑registered pharmacy | Discreet packaging | Personalised care
Start Menopause ConsultationRelated Livial Guides
Medical Content Manager
Nabeel is a co-founder and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up-to-date.
Medical Doctor
Dr. Feroz is a GMC-registered doctor and a medical reviewer at Chemist Doctor. He oversees acute condition and urgent care guidance.
Medical Director
Usman is a co-founder and medical director of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical and operational priorities.
Review Date: 27 March 2026
Next Review: 27 September 2026
Published on: 27 March 2026
Last Updated: 27 March 2026